Warts - Pipeline Review, H2 2017

Date: July 18, 2017
Pages: 86
Price:
US$ 2,000.00 US$ 1,700.00
Offer valid until September 1, 2017!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: W135F27F72BEN
Leaflet:

Download PDF Leaflet

Warts - Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Warts - Pipeline Review, H2 2017, provides an overview of the Warts (Infectious Disease) pipeline landscape.

Warts are skin growth that is caused by virus called human papillomavirus (HPV). HPV infects the top layer of skin, usually entering the body in an area of broken skin. The virus causes the top layer of skin to grow rapidly, forming a wart. Symptoms include pain and rough skin. Predisposing factors include age and people with weakened immune systems, such as those with HIV/AIDS or people who had organ transplants.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Warts - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Warts (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Warts (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Warts and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 16, 1, 6 and 3 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.

Warts (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Warts (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Warts (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Warts (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Warts (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Warts (Infectious Disease)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Warts (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Warts (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Warts - Overview
Warts - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Warts - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Warts - Companies Involved in Therapeutics Development
Aclaris Therapeutics Inc
Agilvax Inc
Aviragen Therapeutics Inc
BioMAS Ltd
Cutanea Life Sciences Inc
Cytovation AS
Foamix Pharmaceuticals Ltd
G&E Herbal Biotechnology Co Ltd
Laboratories Ojer Pharma SL
LEO Pharma A/S
Nielsen Biosciences Inc
Novan Inc
Novartis AG
Promius Pharma LLC
RXi Pharmaceuticals Corp
Tamir Biotechnology Inc
Zydus Cadila Healthcare Ltd
Warts - Drug Profiles
(digoxin + furosemide) - Drug Profile

854-A - DRUG PROFILE

Albicin - Drug Profile
AS-101 - Drug Profile
AX-03 - Drug Profile
BTA-074 - Drug Profile
CyPep-1 - Drug Profile
DFD-05 - Drug Profile
FIT-039 - Drug Profile
furosemide - Drug Profile
human papillomavirus [serotypes 6, 11] (bivalent) vaccine - Drug Profile
human papillomavirus vaccine - Drug Profile
human papillomavirus vaccine - Drug Profile
hydrogen peroxide - Drug Profile
imiquimod - Drug Profile
imiquimod SR - Drug Profile
ingenol mebutate - Drug Profile
interferon alfa-2b - Drug Profile
LFX-453 - Drug Profile
omiganan pentahydrochloride - Drug Profile
povidone iodine - Drug Profile
PP-210 - Drug Profile
ranpirnase - Drug Profile
RKP-00156 - Drug Profile
Samcyprone - Drug Profile
SB-206 - Drug Profile
SRT-100 - Drug Profile
VP-100 - Drug Profile
Warts - Dormant Projects
Warts - Discontinued Products
Warts - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Warts, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Warts - Pipeline by Aclaris Therapeutics Inc, H2 2017
Warts - Pipeline by Agilvax Inc, H2 2017
Warts - Pipeline by Aviragen Therapeutics Inc, H2 2017
Warts - Pipeline by BioMAS Ltd, H2 2017
Warts - Pipeline by Cutanea Life Sciences Inc, H2 2017
Warts - Pipeline by Cytovation AS, H2 2017
Warts - Pipeline by Foamix Pharmaceuticals Ltd, H2 2017
Warts - Pipeline by G&E Herbal Biotechnology Co Ltd, H2 2017
Warts - Pipeline by Laboratories Ojer Pharma SL, H2 2017
Warts - Pipeline by LEO Pharma A/S, H2 2017
Warts - Pipeline by Nielsen Biosciences Inc, H2 2017
Warts - Pipeline by Novan Inc, H2 2017
Warts - Pipeline by Novartis AG, H2 2017
Warts - Pipeline by Promius Pharma LLC, H2 2017
Warts - Pipeline by RXi Pharmaceuticals Corp, H2 2017
Warts - Pipeline by Tamir Biotechnology Inc, H2 2017
Warts - Pipeline by Zydus Cadila Healthcare Ltd, H2 2017
Warts - Dormant Projects, H2 2017
Warts - Discontinued Products, H2 2017

LIST OF FIGURES

Number of Products under Development for Warts, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017
Skip to top


Trophos SA - Product Pipeline Review - 2014 US$ 1,275.00 Jan, 2014 · 37 pages

Ask Your Question

Warts - Pipeline Review, H2 2017
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: